Publications by authors named "Juan Carlos Martinez-Castrillo"
Background And Objective: Staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (Motor; Non-motor; Cognition; Dependency) and five stages, correlated with disease severity, patients' quality of life and caregivers' strain and burden. Our aim was to apply the MNCD classification in advanced PD patients treated with device-aided therapy (DAT).
Patients And Methods: A multicenter observational retrospective study of the first patients to start the levodopa-entacapone-carbidopa intestinal gel (LECIG) in Spain was performed (LECIPARK study).
Introduction: In Parkinson's Disease (PD), despite available treatments focusing on symptom alleviation, the effectiveness of conventional therapies decreases over time. This study aims to enhance the identification of candidates for device-aided therapies (DAT) using artificial intelligence (AI), addressing the need for improved treatment selection in advanced PD stages.
Methods: This national, multicenter, cross-sectional, observational study involved 1086 PD patients across Spain.
Background And Purpose: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed device-aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real-world evidence about the effectiveness, tolerability, and safety of LECIG in PD patients.
Methods: A multicenter observational retrospective study of the first patients who initiated LECIG in Spain was performed.
Article Synopsis
- * Assessments were conducted using EEG and various cognitive and quality of life tests at the start, and after 3 and 6 months, showing some initial positive effects that diminished over time due to habituation.
- * Results indicated variable individual responses, with over half the participants experiencing a reduction in theta band power, along with subtle improvements in cognitive and quality of life measures.
Parkinson's disease (PD) is a complex disease, and the treatment is focused on the patient's clinical symptoms. Levodopa continues to be the most effective drug for symptomatic PD treatment. However, chronic levodopa treatment is associated with the development of motor complications in most patients.
View Article and Find Full Text PDFArticle Synopsis
- Dopamine replacement therapy is crucial for managing motor and nonmotor symptoms in Parkinson's disease, but treatment adjustments become necessary as the disease progresses.
- The study aimed to validate the OPTIMIPARK questionnaire, which assesses patient symptoms, to aid clinicians in making treatment decisions for those on levodopa.
- Results showed that the OPTIMIPARK score led to more patients needing treatment changes compared to standard evaluations, suggesting it could be a more effective tool for determining therapeutic needs in Parkinson's patients.
Introduction: Coronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease.
Objective: To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes.
Background And Purpose: Reduced facial expression of emotions is a very frequent symptom of Parkinson's disease (PD) and has been considered part of the motor features of the disease. However, the neural correlates of hypomimia and the relationship between hypomimia and other non-motor symptoms of PD are poorly understood.
Methods: The clinical and structural brain correlates of hypomimia were studied.
Background: For specialists in charge of Parkinson's disease (PD), one of the most time-consuming tasks of the consultations is the assessment of symptoms and motor fluctuations. This task is complex and is usually based on the information provided by the patients themselves, which in most cases is complex and biased. In recent times, different tools have appeared on the market that allow automatic ambulatory monitoring.
View Article and Find Full Text PDFBackground: Blood homocysteine appears to be increased in Parkinson's disease (PD) and may play a role in the development and progression of this disorder. However, the specific contribution of abnormal homocysteine levels to cortical degeneration in PD remains elusive.
Objective: To characterize the cortical structural correlates of homocysteine levels in PD.
: Parkinson's disease (PD) is a clinically heterogeneous disorder in which the symptoms and prognosis can be very different among patients. We propose a new simple classification to identify key symptoms and staging in PD. : Sixteen movement disorders specialists from Spain participated in this project.
View Article and Find Full Text PDFBackground: Clinical diagnosis of atypical parkinsonisms may be challenging. The eye-of-the-tiger sign on brain MRI, typical of neurodegeneration with brain iron accumulation, has been anecdotally observed in cases clinically diagnosed as atypical parkinsonisms.
Objectives: To show how clinical syndromes and even neuroimaging sometimes may lead the neurologist to a misunderstanding, just as to emphasize the important role of pathology to establish the final diagnosis in these cases.
Article Synopsis
- Advanced Parkinson's Disease (APD) is characterized by severe symptoms and a poor response to standard treatments, but its prevalence has not been well-studied historically.
- The study aimed to assess the prevalence of APD among patients with idiopathic Parkinson's disease in Spanish hospitals, while also examining the broader characteristics of PD patients.
- Findings revealed that 38.2% of patients had APD, with relevant statistics on demographic factors, co-morbidities, quality of life, and treatment options available for advanced stages of the disease.
Background: Identifying modifiable risk factors for cognitive impairment in the early stages of Parkinson's disease (PD) and estimating their impact on cognitive status may help prevent dementia (PDD) and the design of cognitive trials.
Methods: Using a standard approach for the assessment of global cognition in PD and controlling for the effects of age, education and disease duration, we explored the associations between cognitive status, comorbidities, metabolic variables and lifestyle variables in 533 PD participants from the COPPADIS study.
Results: Among the overall sample, 21% of participants were classified as PD-MCI (n = 114) and 4% as PDD (n = 26).
Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.
View Article and Find Full Text PDFBackground: Parkinson's disease (PD) patients, especially those on dopamine agonists (DA), are at risk of impulse control disorders (ICD). Little attention has been paid to the influence of environmental factors.
Cases: Retrospective analysis of consecutive PD patients seen in our outpatient Movement Disorders Clinic during 2 months (September-November 2020) to explore the frequency of ICD during the preceding 2-month lockdown period, and comparison with an equivalent control group (September-November 2019).
Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol.
BMJ Open
July 2021
Introduction: In recent years, multiple studies have aimed to develop and validate portable technological devices capable of monitoring the motor complications of Parkinson's disease patients (Parkinson's Holter). The effectiveness of these monitoring devices for improving clinical control is not known.
Methods And Analysis: This is a single-blind, cluster-randomised controlled clinical trial.
Background: There is a need for identifying risk factors for hospitalization in Parkinson's disease (PD) and also interventions to reduce acute hospital admission.
Objective: To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort.
Methods: PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study.
Background: We aimed to assess the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson's disease (PD).
Methods: We retrospectively analyzed the data of patients at 1 and 3 months of follow-up compared to baseline.
Results: = 82 (safinamide 50 mg = 22, 100 mg = 60, with antidepressants = 44).
Background: Impulse control disorders (ICDs) have an increased frequency in patients with Parkinson's disease (PD), mainly because of treatment with dopamine agonists (DA). Factors related with the country of origin (culture, economy, healthcare politics) may impact phenomenology.
Objectives: To explore phenomenology of ICDs depending on the country.